Karyopharm Therapeutics stock (US48576U1060): Q1 revenue beats estimates, trial enrollment complete

Karyopharm Therapeutics reported Q1 2026 revenue of $35.1M, beating forecasts, with U.S. XPOVIO net product revenue up to $29.2M. Company completed Phase 3 endometrial cancer trial enrollment and reaffirmed full-year guidance of $130M-$150M.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) released its first quarter 2026 financial results on May 14, 2026, showing total revenue of $35.1 million, surpassing Wall Street expectations of $33.9 million according to WTOP News as of 05/14/2026. U.S. net product revenue from XPOVIO (selinexor) rose to $29.2 million from $21.1 million a year earlier, as detailed in the company's press release as of 05/14/2026. The firm also announced completion of enrollment in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with topline data expected mid-2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Karyopharm Therapeutics Inc.
• Sector/industry: Biotechnology / Oncology
• Headquarters/country: Newton, Massachusetts, USA
• Core markets: United States, Europe
• Key revenue drivers: XPOVIO sales, royalties
• Home exchange/listing venue: Nasdaq (KPTI)
• Trading currency: USD

Karyopharm Therapeutics: core business model

Karyopharm Therapeutics is a commercial-stage biopharmaceutical company focused on novel cancer therapies using its proprietary Selective Inhibitor of Nuclear Export (SINE) technology. The lead product, XPOVIO (selinexor), is an oral agent approved for multiple myeloma and diffuse large B-cell lymphoma in the U.S. and several other indications globally. XPOVIO targets exportin 1 (XPO1), a protein involved in oncogenesis, enabling treatment of cancers reliant on nuclear transport dysregulation.

The company generates revenue primarily from XPOVIO net product sales in the U.S., supplemented by license, royalty, and milestone payments from international partners. For Q1 2026 ended March 31, 2026, total revenue reached $35.1 million, with U.S. XPOVIO contributing $29.2 million, per the PR Newswire release as of 05/14/2026. This model supports ongoing R&D in oncology, with a pipeline including Phase 3 trials in endometrial cancer.

Main revenue and product drivers for Karyopharm Therapeutics

XPOVIO remains the cornerstone, driving 83% of Q1 2026 revenue at $29.2 million, up 38% year-over-year. Growth reflects expanded U.S. market access and physician adoption in approved indications. Karyopharm reaffirmed 2026 full-year U.S. XPOVIO guidance of $115 million to $130 million, part of total revenue outlook $130 million to $150 million, as stated in the Q1 report published May 14, 2026.

International royalties from partners like Menarini in Europe and Asia provide additional streams. Pipeline milestones, such as the completed Phase 3 XPORT-EC-042 enrollment, could unlock further revenue via potential approvals. Phase 3 SENTRY results are slated for presentation at ASCO on June 2, 2026, per the press release.

Industry trends and competitive position

The oncology sector sees robust demand for targeted oral therapies, with the U.S. market for multiple myeloma treatments exceeding $20 billion annually as of recent sector reports. Karyopharm's SINE compounds differentiate in nuclear export inhibition, a niche with limited direct competitors. XPOVIO's approvals position it against standards like Revlimid and Darzalex.

Endometrial cancer trials tap into a growing U.S. market, where advanced cases represent significant unmet need. Karyopharm's progress in Phase 3 studies enhances its competitive stance amid biotech M&A activity.

Why Karyopharm Therapeutics matters for US investors

Listed on Nasdaq, Karyopharm offers U.S. investors direct exposure to innovative oncology drugs with commercial traction. XPOVIO's U.S. sales growth underscores revenue potential in the world's largest pharma market. Clinical catalysts like mid-2026 topline data and ASCO presentation provide near-term focus points relevant to American portfolios tracking biotech innovation.

Conclusion

Karyopharm Therapeutics delivered solid Q1 2026 results with revenue beats and key clinical progress, including trial completion and reaffirmed guidance. U.S. XPOVIO sales momentum supports the outlook amid pipeline advancements. Investors track upcoming ASCO data and topline results for further insights into growth trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.